Shares of Amgen (AMGN) are down $11.49, or 4%, to $282.51 in pre-market trading after the company reported data at 52 weeks in a Phase 2 study with MariTide – maridebart cafraglutide, formerly AMG 133 – an investigational antibody peptide conjugate subcutaneously administered monthly or less frequently for people living with obesity.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AMGN:
- Amgen’s MariTide shows up to 20% average weight loss in Phase 2 study
- Eli Lilly, others to buy after RFK-inspired drop, Barron’s says
- Amgen appoints Howard Chang as SVP of Research and Chief Scientific Officer
- Viridian Therapeutics (VRDN) Has Captured Investors’ Attention with Recent Breakthroughs
- Wolfe Research starts Amgen at Peer Perform given approaching patent cliffs
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
